Roche Holding AG (RHHVF)

241.51 -9.28 (-3.70%) 收市：02:50PM EDT

Roche Holding AG

Grenzacherstrasse 124
Basel 4058
Switzerland
41 61 688 11 11
https://www.roche.com

版塊: Healthcare
行業: Drug Manufacturers - General
全職員工: 103,605

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Severin Schwan Ph.D.	Executive Chairman	8.23M	無	1967
Dr. Thomas Schinecker	Chief Executive Officer	4.24M	無	1975
Dr. Alan Hippe	Chief Financial & Information Officer	4.5M	無	1967
Dr. Bruno Eschli	Head of Investor Relations	無	無	無
Ms. Claudia Bockstiegel	General Counsel	無	無	1964
Ms. Pascale Schmidt	Chief Compliance Officer	無	無	1973
Ms. Barbara Schadler	Head of Group Communications	無	無	1962
Ms. Cristina A. Wilbur	Chief People Officer	3.2M	無	1967
Dr. Nicolas Dunant	Head of Group Media Relations	無	無	無
Mr. Boris L. Zaitra	Head of Group Business Development and M&A	無	無	1972

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.

公司管治

截至 2024年4月1日 止，Roche Holding AG 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中：4；董事會：6；股東權利：9；現金賠償：8。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。